- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | Gilead's lenacapavir moves closer to FDA approval for HIV PrEP use | ||
| Di | Valneva hits 2024 sales target but plans lower cash burn in 2025 | ||
| Di | EC conditionally approves MSD's Welireg for VHL disease and RCC | ||
| Di | FDA to review Sanofi and Regeneron's Dupixent sBLA for bullous pemphigoid | ||
| Di | HMRI and Novartis Australia sign MoU to expedite medical research | ||
| Di | FDA grants fast track status to Rznomics' RZ-001 for HCC | ||
| Mo | Ono's TGCT therapy wins FDA approval, challenging Daiichi Sankyo | ||
| Mo | Oncology and eClinical solutions: How one company is adapting to the challenges | ||
| Mo | Innate's lacutamab gains FDA breakthrough therapy designation | ||
| Mo | Bispecific antibody startup Bambusa raises $90m to fund clinical trials | ||
| Mo | Bavarian Nordic scoops FDA approval for chikungunya vaccine in adults and teens | ||
| Mo | GSK's Penmenvy meningococcal vaccine gains FDA approval | ||
| Mo | Moderna reports decline in Q4 2024 revenue | ||
| 14.02. | EC approves CSL's Andembry to stop hereditary angioedema attacks | ||
| 14.02. | DMD market expected to grow to $5.2bn in the 7MM by 2033 | ||
| 14.02. | Galderma enters fierce European atopic dermatitis market with Nemluvio approval | ||
| 14.02. | EU reshapes HTAs: is the industry ready for it? | ||
| 14.02. | Newleos secures $93.5m for neuropsychiatric treatments | ||
| 14.02. | Health Canada approves Novartis' Fabhalta for PNH with haemolytic anaemia | ||
| 13.02. | Revolutionary approaches to drug design: how AI is transforming life sciences | ||
| 13.02. | Aardvark Therapeutics prices $94.2m IPO to fund development of Prader-Willi syndrome drug | ||
| 13.02. | Trump presidency signals potential downturn in NIH SBIR/STTR grant funding for biopharma drugs | ||
| 13.02. | SmartCella gains rights to advance cell therapy research for Parkinson's | ||
| 13.02. | US Government actions having a serious impact on global health, WHO chief says | ||
| 13.02. | Royalty Pharma pays $250m for rights to Biogen's lupus drug |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
